US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Aclarion Inc.
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
July 20, 2022
From
Aclarion Inc.
Via
AccessWire
Tickers
ACON
ACONW
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
June 22, 2022
From
Aclarion Inc.
Via
AccessWire
Tickers
ACON
ACONW
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
April 26, 2022
From
Aclarion Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Tickers
ACON
ACONW
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering
April 21, 2022
From
Aclarion Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance